Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

NCT03891706 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: tumor-specific TCR-T cells
DRUG: Interleukin-2

Sponsor

Guangzhou FineImmune Biotechnology Co., LTD.

Collaborators

[object Object]